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Accuracy, reliability, feasibility and nurse 
acceptance of a subcutaneous continuous 
glucose management system in critically ill 
patients: a prospective clinical trial
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Abstract 
Background: Continuous glucose monitoring (CGM) has not yet been implemented in the intensive care unit 
(ICU) setting. The purpose of this study was to evaluate reliability, feasibility, nurse acceptance and accuracy of the 
Medtronic Sentrino® CGM system in critically ill patients.
Methods: Sensors were inserted into the subcutaneous tissue of the patient’s thigh, quantifying interstitial glucose 
concentration for up to 72 h per sensor. Reliability and feasibility analysis included frequency of data display, data 
gaps and reasons for sensor removal. We surveyed nurse acceptance in a questionnaire. For the accuracy analysis, we 
compared sensor values to glucose values obtained via blood gas analysis. Potential benefits of CGM were investi‑
gated in intra‑individual analyses of factors, such as glycemic variability or time in target range achieved with CGM 
compared to that achieved with intermittent glucose monitoring.
Results: The device generated 68,655 real‑time values from 31 sensors in 20 critically ill patients. 532 comparative 
blood glucose values were collected. Data were displayed during 32.5 h [16.0/62.4] per sensor, which is 45.1 % of the 
expected time of 72 h and 84.8 % of 37.9 h actual monitoring time. 21 out of 31 sensors were removed prematurely. 
79.1 % of the nursing staff rated the device as not beneficial; the response rate was one‑third. Mean absolute rela‑
tive difference was 15.3 % (CI 13.5–17.0 %). Clarke error grid: 76.9 % zone A, 21.6 % zone B, 0.2 % zone C, 0.9 % zone 
D, 0.4 % zone E. Bland–Altman plot: mean bias +0.53 mg/dl, limits of agreement +64.6 and −63.5 mg/dl. Accuracy 
deteriorated during elevated glycemic variability and in the hyperglycemic range. There was no reduction in dysgly‑
cemic events during CGM compared to 72 h before and after CGM. If CGM was measuring accurately, it identified 
more hyperglycemic events when compared to intermittent measurements. This study was not designed to evaluate 
potential benefits of CGM on glucose control.
Conclusions: The subcutaneous CGM system did not perform with satisfactory accuracy, feasibility, or nursing 
acceptance when evaluated in 20 medical‑surgical ICU patients. Low point accuracy and prolonged data gaps 
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Background
Critically ill patients frequently experience stress-induced 
alterations in glucose homoeostasis resulting in hypergly-
cemia [1]. Peripheral insulin resistance and an enhanced 
hepatic glucose production, caused by a release of counter-
regulatory hormones and cytokines, are contributing mech-
anisms [1, 2]. Insufficient GLUT4 translocation in skeletal 
muscle of critically ill patients is related to glucose dysregu-
lation [3]. Hyperglycemia, elevated glycemic variability and 
hypoglycemia, were associated with an increased mortality 
risk in critically ill patients [4–6]. Randomized controlled 
trials showed that insulin therapy and management of glyce-
mic control in the ICU remains challenging [6–10].
Continuous glucose monitoring (CGM) in the ICU, 
combined with an appropriate insulin protocol, may 
improve management of glycemic control and conse-
quently impact patient outcome [11–13]. Wernerman 
et al. provided an overview of CGM technologies, includ-
ing glucose oxidase, mid-infrared spectroscopy and fluo-
rescence, ranging from invasive intravascular devices to 
minimally invasive interstitial and noninvasive transcu-
taneous systems [11]. Interstitial devices designed for use 
in diabetic patients have already been applied in critically 
ill patients [13–16]. Despite promising attempts, these 
systems have not yet been implemented to daily routine 
in the ICU and improvements are desirable. The subcu-
taneous Medtronic Sentrino® CGM system was designed 
for use in ICU patients. The displayed real-time glucose 
trend line allows the ICU staff to observe glucose excur-
sions at an earlier stage when compared to the established 
intermittent measurements. Patients may benefit from 
increased time in target range and improved glycemic 
variability. In addition, nurse workload may be reduced.
The purpose of this study was to evaluate reliability, 
feasibility, nurse acceptance and accuracy of this subcuta-
neous CGM system, as well as to identify potential weak-
nesses of the device in severely ill patients. In addition 
to previous studies [17–19], we retrospectively assessed 
potential benefits of CGM in comparison with intermit-
tent glucose monitoring in our medical-surgical ICU.
Methods
Inclusion criteria and study participants
Inclusion criteria included an expected length of stay 
in the ICU of at least 72  h, age ≥18  years and written 
informed consent given by patient or legal proxy. We 
recruited critically ill patients during a time period of 
seven months in 2014. Patient inclusion started immedi-
ately after the local ethics committee, Ethikkommission 
Charité Universitätsmedizin Berlin, approved the study 
protocol (Charité-EA2/095/14). The protocol was reg-
istered under https://clinicaltrials.gov, trial registration 
number NCT02296372.
Glycemic control in the study setting
The single-center study was set in two interdisciplinary 
mixed medical-surgical ICUs of a university hospital. The 
glucose target levels for insulin therapy were 80–149 mg/
dl. Dysglycemic events were defined as follows: ranges 
above 149  mg/dl represented moderate hyperglycemia, 
and glucose levels above 179  mg/dl represented severe 
hyperglycemia. Moderate hypoglycemia was defined in a 
range from 41 to 70 mg/dl, and severe hypoglycemia as 
≤40 mg/dl [11, 20]. Due to general ICU routine, nurses 
took blood samples from an arterial catheter in 2- to 4-h 
intervals, depending on the patient’s condition. In the 
absence of an arterial line, blood was collected from a 
central or peripheral venous catheter. Blood glucose was 
determined by glucose oxidase reaction using a Radi-
ometer ABL 800 FLEX (Copenhagen, Denmark) blood 
gas analyzer. Depending on the identified blood glucose 
value, the nursing staff regulated the intravenous insulin 
therapy according to the local insulin protocol (Addi-
tional file 1: Table S1). All patient data, including blood 
gas analyses, were documented within the patient data 
management system (PDMS).
CGM sensor
According to manufacturer’s information, the sensors of 
the interstitial CGM device consist of four independently 
working electrodes, which are embedded in two cannu-
las. This multisensory system provides enhanced signal 
stability and accuracy in critically ill patients. The elec-
trodes are coated by glucose oxidase. In the enzymatic 
reaction, electrons are released and create an electrical 
gradient, which is proportional to the interstitial glu-
cose concentration. Based on the electrical signal, the 
CGM algorithm calculates out of the four data signals 
one blood glucose value, which is displayed on a bed-
sided monitor. The device provides one real-time glucose 
significantly limited the potential clinical usefulness of the CGM trend data. Accurate continuous data display, with a 
MARD < 14 %, showed potential benefits in a subgroup of our patients.
Trial registration NCT02296372; Ethic vote Charité EA2/095/14
Keywords: Continuous glucose monitoring, Subcutaneous, Interstitial, Critically ill patients, ICU, Medtronic Sentrino®, 
Accuracy, Reliability, Feasibility, Nurse acceptance, Evaluation
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measurement per minute, with an insignificant lag time 
for signal processing, for up to 72 h (for more details, see 
Additional file 1: CGM Device).
Study procedure
We inserted the sensors into the subcutaneous tissue of 
patient’s upper leg. After initialization, the sensors required 
one initial blood glucose entry, followed by two further 
calibrations after the first and second running hour. Sub-
sequently, the study team performed calibrations every 8 h, 
as proposed by the manufacturer. The ward staff were not 
required to perform further calibrations. We instructed 
nurses to observe the continuous glucose trend line and 
perform blood glucose measurements to adapt insulin 
therapy in case of excursions above or below the target 
range (defined in the local insulin protocol Additional file 1: 
Table S1). Glucose values determined by the blood gas ana-
lyzer were used as reference. Blood glucose measurements 
used for initial calibrations and calibrations after data gaps 
(>15 min) were excluded from the point accuracy analysis. 
Further blood glucose measurements were included and 
compared to the latest CGM value immediately before cali-
bration. As specified in the study protocol (Fig. 1), the accu-
racy analysis required a minimum monitoring time of 48 h 
or at least 12 comparative readings.
Analysis criteria
Figure  2 illustrates detailed endpoints for the analysis 
of reliability, feasibility, nurse acceptance, accuracy and 
potential benefits of CGM. The analysis is based on the 
2013 consensus recommendations, published by Fin-
fer et al. defining criteria for continuous glucose control 
in critically ill patients [20]. Desirable reliability criteria 
include a continuous data display during >95  % of time 
and device-related data gaps <30  min [20]. We cal-
culated frequency of data gaps and analyzed the gaps 
subdivided as very brief (<15  min), brief (15–30  min), 
prolonged (>30  min) and very prolonged (>2  h), so as 
to better describe the clinical significance of the miss-
ing trend data. The feasibility analysis considered the 
capacity of the device to perform within the busy ICU 
setting. This was supplemented by a survey of nurse 
acceptance assessed by brief questionnaires given to the 
nurses in charge of each shift (Additional file 1: Fig. S3). 
To determine accuracy, sensor values were compared to 
the simultaneously recorded blood glucose values from 
PDMS. We calculated point accuracy according to cri-
teria specified within the consensus recommendations 
[20], which can be summarized as follows
  • 98 % of device readings should be within 12.5 % of a 
reference standard (or within ±10 mg/dl for readings 
<100 mg/dl)
  • The remaining 2 % of readings should be within 20 % 
of a reference standard
  • Mean absolute relative difference (MARD) should 
be <14 % (M)ARD = │(blood glucose − sensor glu-
cose)│/blood glucose × 100
  • MARD > 18 % represents poor accuracy.
In addition, we analyzed possible confounding factors 
on MARD, such as arterial pO2, temperature, hemo-
globin, potassium, lactate, pH value, sequential organ 
failure assessment (SOFA) Score, systemic inflamma-
tory response syndrome (SIRS), history of diabetes, 
blood glucose variability and glucose ranges (<80  mg/
dl, 80–179  mg/dl, >179  mg/dl). We retrospectively cal-
culated MARD after time-shifting the reference a fixed 
amount (1 up to 30 min), so as to investigate a time delay 
as a possible confounding factor. To investigate potential 
benefits of CGM in our ICU, we report glycemic con-
trol achieved with CGM compared to that achieved with 
intermittent glucose monitoring. This was accomplished 
by performing intra-individual analyses, longitudinal 
and parallel, of factors such as mean blood glucose level, 
blood glucose variability, number of dysglycemia events 
and time in blood glucose target range (Fig. 2). Glycemic 
variability was determined using standard deviation of 
blood glucose and glycemic lability index (Table 4b), as a 
Fig. 1 Study procedure. We included n = 20 patients during 57 days 
of recruiting. One patient was excluded from the accuracy analysis 
due to a lack of comparative blood glucose samples. Ten patients 
required a second sensor to achieve the minimum number of com‑
parative samples or a minimum running time of 48 h. We used an 
optional second sensor in one patient
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time-weighted index [21]. To evaluate safety, we reported 
local complications and discussed patient risks due to 
inaccurate CGM measurements in a safety statement.
Statistical analysis
Results were shown as median with interquartile range 
or as absolute numbers with percentages. Clinical accu-
racy was illustrated using Bland–Altman plot [22], Clarke 
error grid [23] and Surveillance Error-Grid [24]. We cal-
culated glycemic lability index using EasyGV© software 
[21]. Nonparametric tests were performed (Mann–Whit-
ney U Test, Wilcoxon Test, Kruskal–Wallis Test, Fried-
man Test and Spearman’s correlation). We used IBM© 
SPSS© Statistics version 21, Microsoft Excel© 2010 and R 
for the statistical analysis.
Results
We included 20 critically ill patients in this prospective 
trial using a total of 31 sensors (Fig.  1). Table  1 shows 
patient characteristics. In total, the device generated 
68655 (1144.3 h) real-time glucose values during 1337.1 h 
of monitoring. The median monitoring time per patient 
was 70.5  h [57.2/72.7]. For the accuracy comparison, 
we collected 532 blood glucose values in 19 patients, of 
which 475 (89.3  %) were obtained from arterial and 57 
(10.7 %) from venous catheters. There was no significant 
difference in accuracy between the 475 arterial blood glu-
cose values compared to all 532 glucose values (p = .799). 
Table 2 shows a summary of glycemic control metrics.
Reliability, feasibility and safety
The reliability analysis showed a real-time data display 
during 32.5  h (16/62.4) per sensor, which is 45.1  % of 
the expected time of 72 h and 84.8 % of the 37.9 h actual 
monitoring time. During 80223 min (1337.1 h) of moni-
toring, we observed in total 11568 min (192.8 h) of miss-
ing values. The number of data gaps was 155, of which 68 
(43.9 %) were very brief (<15 min), 35 (22.6 %) were brief 
(15–30  min), 27 (17.4  %) were prolonged (30–120  min) 
and 25 (16.1  %) were very prolonged. The sensor inser-
tion itself was easily performed and required less than 
10 min. The complication rate at the site was low. Minor 
bleeding after insertion occurred in four patients. We 
observed no local infection. The main feasibility issue 
was premature sensor removal. Detailed device reliability 
and feasibility is shown in Table 3.
Fig. 2 Analysis criteria. Detailed criteria for the evaluation of subcutaneous CGM in the ICU
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Table 1 Patient characterization
n = 20 patients
Results are expressed as median with interquartile range or as absolute numbers with percentages of n = 20 patients
BMI body mass index, ARDS acute respiratory distress syndrome, ECMO extracorporeal membrane oxygenation, ECLA extracorporeal lung assist, SIRS systemic 
inflammatory response syndrome, SOFA sequential organ failure assessment, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, CGM 
continuous glucose monitoring
Age 61 [54/69]
Gender (female/male) 14 (70 %)/6 (30 %)
BMI (kg/m2) 23 [22/26]
Diagnosis leading to ICU stay
 ARDS (ECMO, ECLA) 6 (30 %)
 ARDS (without ECMO, ECLA) 8 (40 %)
 Mediastinitis 1 (5 %)
 Peritonitis 3 (15 %)
 Intracranial hemorrhage 1 (5 %)
 Polytrauma 1 (5 %)
At least one event of SIRS or sepsis during CGM 20 (100 %)
Sequential organ failure assessment (SOFA) Score at inclusion 8 [4/10]
Acute physiology and chronic health evaluation (APACHE) 2 Score at admission 24 [19/28]
History of diabetes mellitus 5 (25 %)
Administration of intravenous insulin therapy during CGM 14 (70 %)
Administration of vasopressors during CGM 7 (35 %)
Mean dose of epinephrine during sensor running time (µg/kg/min) (in seven patients receiving vasopressors) 0.08 [0.03/0.14]
Mortality during ICU stay 4 (20 %)
Table 2 Mean glucose level, glycemic variability and glycemic events
n = 19 patients
Results are expressed as median with interquartile range or as absolute numbers with percentages
SD standard deviation
* p = 1.0; § p = 0.002
Reference blood glucose Comparative CGM reading
Number of comparative glucose readings 532 532
Readings per patient 28 [18/34] 28 [18/34]
Mean glucose level per patient (mg/dl) 133.8 [128.4/147.5] 133.7 [124.3/150.1]*
Glucose variability per patient measured in  
SD (mg/dl)
24.8 [19.9/35.2] 32.5 [25.2/42.2]§
Glycemic events: number and percentage of n = 19 patients
 Severe hypoglycemia (≤40 mg/dl) 1 (5.3 %) 1 (5.3 %)
 Moderate hypoglycemia (41–70 mg/dl) 1 (5.3 %) 10 (52.6 %)
 Euglycemia (71–149 mg/dl) 19 (100 %) 19 (100 %)
 Moderate hyperglycemia (150–179 mg/dl) 18 (94.7 %) 19 (100 %)
 Severe hyperglycemia (>179 mg/dl) 15 (78.9 %) 11 (57.9 %)
Glycemic events: number and percentage of 
n = 532 readings
158 (29.7 %) 188 (35.3 %)
 Severe hypoglycemia (≤40 mg/dl) 1 (0.2 %) 1 (0.2 %) Chi‑square test: p < 0.001 for crosstabulation see 
supplement Moderate hypoglycemia (41–70 mg/dl) 2 (0.4 %) 15 (2.8 %)
 Euglycemia (71–149 mg/dl) 374 (70.3 %) 344 (64.7 %)
 Moderate hyperglycemia (150–179 mg/dl) 96 (18.0 %) 101 (19 %)
 Severe hyperglycemia (>179 mg/dl) 59 (11.1 %) 71 (13.3 %)
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Nurse acceptance
The nurses received 128 questionnaires during the CGM 
monitoring period. The response rate was one-third 
(n = 43, 34 %). The majority (79.1 %) of the nursing staff 
rated the device as not beneficial in the daily ICU rou-
tine. Advantages, such as the opportunity to observe 
glucose trends, were reported in 20.9 % of the question-
naires. Disadvantages were described by 53.5 %. Reasons 
included the inadequate alarm performance (23.3  %), 
the additional device (23.3 %) and device line (6.9 %) as 
disturbing factors during bedding and mobilization in the 
ICU routine.
Point accuracy
60.3 % of sensor data were within 12.5 % from the refer-
ence blood glucose (or were within ±10 mg/dl for read-
ings <100 mg/dl). In total, 76.9 % of sensor readings were 
within 20, and 23.1 % deviated more than 20 % from the 
reference. MARD was 15.3  % (95  % CI 13.5–17.0  %). 
Spearman’s correlation coefficient was 0.688, p  <  .001, 
Table 3 Reliability and feasibility
n = 20 patients, 31 sensors
Results are expressed as median with interquartile range or as absolute numbers with percentages
MRI magnetic resonance imaging
Per sensor
Initialization time 27 min
Total time until first displayed value 37.5 min [36/42]
Expected monitoring time after initialization 72 h
Actual monitoring time after initialization 37.9 h [23/71.3]
 Real‑time data display 32.5 h [16/62.4]
 Percentage of real‑time data display/expected monitoring time after initialization 45.1 %
 Percentage of real‑time data display/actual monitoring time after initialization 84.8 % [67.9/93.8]
Data gaps after initialization 5 h [1.9/8.3]
 Percentage of data gaps/actual monitoring time after initialization 15.2 % [6.2/32.1]
 Number of performed calibrations 9.5 [6/13]
Reasons for the 11,568 min  
(192.8 h) of data gaps




1 Poor sensor signal (%) 23.3 3.4
2 Sensor failure (%) 15.0 2.2
3 Processor line error (%) 10.9 1.6
4 Disconnection (%) 15.6 2.3
5 Pending after reconnection (%) 3.4 0.5
6 Calibration required (%) 27.8 4.0
7 Others (%) 4.0 0.6
Device‑related reasons (1–3) (%) 49.2 7.2
Not device related (4–7) (%) 50.8 7.4






Sensors 72 h completed 10 32.3 –
Sensors removed prematurely 21 67.7 100
1 Accidentally 7 22.6 33.3
2 Poor sensor signal during measurement 7 22.6 33.3
3 Poor sensor signal immediately after initialization 1 3.2 4.8
4 MRI 1 3.2 4.8
5 Discharge 1 3.2 4.8
6 Death 2 6.5 9.5
7 Others 2 6.5 9.5
Device‑related reasons (1–3) 15 48.4 71.4
Not device related (4–7) 6 19.4 28.6
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r2  =  0.461. The Bland–Altman plot (Fig.  3a) showed 
a mean bias of 0.53  mg/dl and limits of agreement of 
+64.6  mg/dl and −63.5  mg/dl. Clarke error grid and 
Color-Coded Surveillance Error-Grid (Fig. 3b, c) showed 
potentially dangerous errors. Additional file  1: Table S2 
shows the detection of dysglycemic events.
Confounding factors on accuracy
We identified that the blood glucose variability, analyzed 
in standard deviation, was significantly associated with 
CGM accuracy (Fig. 4a). Confirming this finding, stand-
ard deviation per patient was positively correlated with 
MARD per patient k = 0.593, p = .001, n = 19, r2 = 0.298 
(Additional file  1: Fig. S1). MARD deteriorated in the 
hyperglycemic blood glucose range (Fig.  4a). There was 
no significant improvement or deterioration of MARD 
after time-shifting the reference glucose a fixed amount 
of 1 up to 30 min (Additional file 1: Fig. S2). MARD was 
worse during application of vasoconstrictors (Additional 
file 1: Table S3a). Previously known diabetes mellitus and 
episodes of SIRS did not confound MARD (Additional 
file  1: Table S3a). The severity of disease, measured via 
SOFA Score, showed a minor positive correlation with 
the MARD (k =  0.088, p =  .043, r2 =  0.006, n =  532). 
There was no significant correlation of arterial pO2, tem-
perature, pH value, lactate, hemoglobin, or potassium 
and MARD (Additional file 1: Table S3b).
Potential benefits of CGM in our ICU
In 10 patients with an ICU stay of at least nine consecu-
tive days, the longitudinal analysis showed no significant 
reduction in dysglycemic events during 3  days of CGM 
compared to 72 h before and 72 h after CGM (Table 4a). 
In the parallel analysis, CGM determined significantly 
lower minimal glucose values and detected more hyper-
glycemic events compared to intermittent blood glucose 
values in eight patients, in whom the device displayed 
accurate results with a MARD < 14 % (Table 4b).
Discussion
Reliability, feasibility and nurse acceptance
This prospective study was initially conducted with the 
intention of implementing a minimally invasive, sim-
ple to use CGM device in our ICU, in order to improve 
glycemic control. Unfortunately, application and per-
formance were not as reliable as expected. Numerous 
sensors were removed prematurely, and the percentage 
of data gaps in relation to the expected sensor running 
time exceeded the time specified within the consensus 
recommendations of ICU experts [20]. The fact that we 
did not demand additional calibrations from the nursing 
staff and that they were not involved in troubleshoot-
ing may have contributed to the extent of data gaps and 
the poor performance. Since 7.4 % of data gaps were not 
device related, the data display during 85.6 % of the sen-
sor running time after initialization could be corrected 
to 93  %. The high rate of accidentally removed sensors 
underlines the vulnerable use of the subcutaneous device 
in intensive care. This is supported by the opinion of our 
ICU nursing staff. More experience with a device may 
enhance feasibility. However, device-related issues, which 
are not improvable by experience, occurred frequently. 
Recently published investigations evaluating the same 
device reported minimal differences in reliability, but the 
clinically relevant results were concordant [17–19].
Point accuracy and confounding factors
The subcutaneous device did not fulfill the suggested 
accuracy criteria for CGM in critically ill patients, speci-
fied within the consensus recommendations of ICU 
experts [20]. The distribution in the Clarke error grid 
[23] was unsatisfactory, as all 532 comparative readings 
of this analysis should have been located in zone A or B, 
preferably in zone A. The Surveillance Error-Grid [24], 
which promises to be closer to clinical routine, showed 
similar degrees of risk. In the Bland–Altman plot, the 
mean bias indicated that there was no systematic error 
[22]. However, 95 % of the values were within 128 mg/dl 
of the reference glucose. These wide limits of agreement 
illustrated a high random error [22]. The detection of 
dysglycemia was critical. The results considering MARD 
values within the 12.5 % range, and Clarke error grid and 
Bland–Altman plot are precisely consistent with those 
reported by Van Hooijdonk et al. [17]. Two further stud-
ies showed slightly better accuracy of the same system 
[18, 19]. Although specifically designed for ICU use, the 
investigated subcutaneous device failed to achieve com-
paratively accurate results in all recently published trials 
[17–19], as opposed to the CGM technologies quantify-
ing glucose concentration in the vascular compartment 
of critically ill patients [25–28]. This leads to the conclu-
sion that, with the intention to administrate insulin ther-
apy, the subcutaneous glucose determination is not the 
proper method to estimate blood glucose levels during 
the acute phase of severe illness.
Inaccuracies may be attributed to a physiological time 
delay relating to the glucose diffusion from the plasma to 
the interstitial compartment [29, 30]. In healthy humans 
and diabetes patients, this time delay has been observed 
to range from 0 to 40 min in various studies summarized 
by Scuffi et al. [30]. Rebrin et al. found no evidence that 
physiological delays exceeded 5–10 min and argued that 
device-related processes are responsible for longer peri-
ods [31]. Moreover, Boyne et  al. addressed the issue of 
random inter-sensor time discrepancies, which were 
quantitatively similar to physiological time delays, when 
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comparing measurements of two subcutaneous sensors 
in the same individual [32]. Factors influencing the glu-
cose diffusion rate, such as blood flow, peripheral micro-
circulation, and metabolic rate of subcutaneous tissue 
and adjacent cells, are all frequently altered in critically ill 
patients [11, 33]. We found no indication for a fixed time 
shift, but time delay and interstitial sensor accuracy may 
vary depending on the patient’s condition. There is evi-
dence to support this hypothesis, since the use of vaso-
pressors and a higher SOFA Score downgraded sensor 
accuracy in the present trial. In contrast, the accuracy of 
a subcutaneous CGM device was significantly improved 
in patients with septic shock compared to patients with-
out sepsis [34]. Further studies cited that circulatory 
shock requiring norepinephrine therapy and impaired 
microcirculation had no influence on subcutaneous sen-
sor accuracy [35, 36]. Variable subcutaneous oxygen con-
centration may interfere with the glucose oxidase. We 
did not investigate tissue paO2, but arterial paO2, as a 
correlating factor, had no clinically relevant impact on 
accuracy.
Glucose homeostasis is affected by the peripheral glu-
cose uptake [33]. Inflammation may lead to an insufficient 
GLUT 4 translocation to sarcolemmal membrane [3]. 
This mechanism resulted in an impaired glucose supply 
in skeletal muscle cells in ICU patients [3]. A decreased 
glucose uptake was observed in adipocytes of septic rats 
[37]. We hypothesize that an insufficient GLUT 4 trans-
location may occur in subcutaneous tissue cells of criti-
cally ill patients. This may influence the accuracy of a 
(See figure on previous page.)  
Fig. 3 Bland–Altman plot, Clarke error grid, Color‑coded Surveillance Error‑Grid. n = 532 comparative samples. a Bland–Altman plot. The mean bias 
indicates whether there is a systematic error. Upper and lower limits were calculated by mean bias ±1.96 × standard deviation of the difference 
between BG and sensor glucose and represent random variations around the mean bias. If there is a Gaussian distribution, 95 % of points are located 
between these limits. [22, 41]. b Clarke error grid. Distribution: A = 76.9 %, B = 21.6 %, C = 0.2 %, D = 0.9 %, E = 0.4 %. Zones A (CGM data ≤20 % 
deviation from BG) and B are considered as clinically acceptable zones, whereas values in zones C, D and E are increasingly dangerous for the patient, 
and zone E may lead to adverse therapeutic decisions. [23]. c Color‑coded Surveillance Error‑Grid. The Surveillance Error‑Grid software is available at 
http://www.diabetestechnology.org/SEGsoftware/Surveillance‑Error‑Grid‑Analysis.xlsm. Last Accessed: Dec 11 2015 [24]
Fig. 4 Confounding factors on MARD. a (left): Association between MARD and individual daily blood glucose variability shown in first and second 
standard deviation of reference glucose. First boxplot The CGM device shows acceptable accuracy* (MARD median 10.9 %) if the blood glucose 
variability is low (first standard deviation). Second boxplot Accuracy deteriorates (MARD median 24 %) during increased blood glucose variability 
(second standard deviation). b (right): Association between MARD and blood glucose ranges. Second boxplot The CGM device shows acceptable 
accuracy* (MARD median 8.8 %) in blood glucose ranges between 80 and 179 mg/dl. First and Third boxplots Accuracy deteriorates in the hypo‑
glycemic range (MARD median 65.8 %) and during severe hyperglycemia (MARD median 16 %). *According to criteria specified within the consensus 
recommendations [20], MARD should be <14 %
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subcutaneous CGM device, when compared to blood 
glucose. Consequently, it can still be assumed that sub-
cutaneous CGM reflects actual insulin-dependent tissue 
glucose dynamics, which may be clinically relevant [32].
We identified that the sensor accuracy deteriorated 
in patients with elevated glycemic variability, as well as 
in the hyperglycemic range. Unfortunately, inaccura-
cies of CGM occurred particularly often when the need 
for CGM would have been most beneficial. Delayed dif-
fusion processes become increasingly significant during 
rapid glucose oscillations [30, 33] and may contribute to 
the adverse influence of glucose variability and hypergly-
cemia on sensor performance. In healthy volunteers, the 
interstitial glucose was similar to venous glucose during 
steady-state conditions, but an increased time delay was 
observed when glucose levels were rapidly elevated by 
glucose infusion [38]. We could not confirm the findings 
reported by van Hooijdonk et al. that accuracy was influ-
enced by a history of diabetes [17]. As already assumed 
in this study, inaccuracies in critically ill diabetic patients 
were possibly attributable to glucose fluctuations [17]. 
Although intravascular and interstitial space should be 
Table 4 Potential benefits of CGM in our ICU
Intra-individual longitudinal and parallel analysis, target range 71–149 mg/dl
Results are expressed as median with interquartile range or as absolute numbers with percentages
Glycemic lability index: time interval 1440 min = 24 h, glucose in mg/dl, sampling interval: blood glucose 120 min = 2 h, sensor glucose 1 min
Number of hypoglycemia or hyperglycemia: only events of newly developed hypoglycemia or hyperglycemia were considered in the analysis
BGA blood glucose analysis, SD standard deviation, GLI glycemic lability index
§ Wilcoxon test before and during p = .123; before and after p = .05, during and after p = .005
# Wilcoxon test before and during p = .241, before and after p = .415, during and after p = .013
* BGAs during CGM data gaps and times of temporary system failure are included
Per patient Blood glucose 3 days 
before CGM
Blood glucose 3 days  
during CGM*
Blood glucose 3 days 
after CGM
p value
(a) Longitudinal analysis. Blood glucose  
metrics before/during/after CGM. n = 10 
patients, 998 blood glucose values
Number of BGA 30 [25/40] 35.5 [28/41] 26.5 [22/34] p = .001§
Number of hypoglycemia 0 [0/0] 0 [0/0] 0 [0/0] p = 1.00
Number of hyperglycemia 3 [1/4] 2.5 [1/5] 2 [1/3] p = .779
Time in target (in %) 82.5 [74/98.2] 81.6 [68.9/95.6] 88.7 [81.3/94.3] p = .452
Time <71 mg/dl (in %) 0 [0/0] 0 [0/0] 0 [0/0] p = 1.00
Time >149 mg/dl (in %) 17.5 [1.8/26] 18.4 [4.4/31.1] 11.3 [5.7/15.4] p = .717
Blood glucose min (mg/dl) 89 [80/100] 85 [73/106] 97.5 [85/110] p = .273
Blood glucose max (mg/dl) 173.5 [162/187] 202 [159/218] 166 [153/185] p = .014#
Mean glucose level (mg/dl) 134 [126.1/137.1] 130.7 [123.5/139] 128.5 [120.6/138.4] p = .497
Mean glucose SD (mg/dl) 18.9 [15.8/22.4] 20.7 [17.6/36.4] 16.2 [11.6/24.2] p = .741
Per patient Blood glucose values  
(n = 239)
CGM sensor glucose 
(n = 34056)
p value
(b) Parallel analysis. Comparison of intermittent blood glucose to CGM  
glucose metrics including the total number of CGM readings, n = 8 
patients MARD < 14 %, 239 blood glucose values, 32,044 CGM values
Number of readings 29.5 [26.5/31.5] 3975 [3780/4109] p = .012
Number of hypoglycemia 0 [0/0] 0.5 [0/2] p = .066
Number of hyperglycemia 1 [1/5] 7 [6/18] p = .018
Time in target range (in %) 88.7 [60.7/96.5] 85.2 [57.9/91.6] p = .208
Time <71 mg/dl (in %) 0 [0/0] 0.3 [0/2.3] p = .068
Time >149 mg/dl (in %) 11.3 [3.6/39.3] 14.3 [6.2/40.6] p = .327
Glucose min (mg/dl) 103.5 [87/111.5] 76 [62/91] p = .017
Glucose max (mg/dl) 195 [154.5/211] 186 [178.5/220.5] p = .208
Mean glucose level (mg/dl) 130.2 [124.3/147.9] 128.7 [120.5/147.4] p = .327
Mean glucose SD (mg/dl) 19.9 [14.4/22.7] 20.6 [16.5/28.4] p = .093
Glycemic lability index 38.0 [14/53] 36.9 [18.5/90.7] p = .674
Page 11 of 13Wollersheim et al. Ann. Intensive Care  (2016) 6:70 
considered as different glucose compartments, the sensor 
technology requires blood glucose calibrations [33, 39]. 
This is a major concern, since sensor calibration during 
glucose alterations may subsequently cause and amplify 
inaccuracies [33].
Safety statement
The local complication rate was acceptable, but critical 
safety issues arose as a consequence of inaccurate meas-
urements. Clarke error grid and Surveillance Error-Grid 
showed potentially dangerous situations for the patients. 
Clinicians need to be aware of the fact that this device 
is not safe to guide insulin therapy. Even if used only to 
support common glucose control, this device can lead to 
confusing situations in the ICU routine of glucose man-
agement. As our experience showed, clinicians should 
always critically question the displayed CGM data.
Potential benefits of CGM in our ICU
Glucose monitoring with the CGM system did not 
improve glycemic control in the longitudinal, intra-
individual analysis. Low accuracy, as well as low nurse 
acceptance, may be potential reasons. Besides, the time in 
target of our severely ill patients with and without CGM 
was high. As a consequence, it may be difficult to dem-
onstrate improved control even with a device that had 
reasonable accuracy. Conversely, if CGM was accurate, 
it showed potential benefits. In contrast to the findings 
of Brunner et  al., glycemic variability was not signifi-
cantly different when calculated from accurate continu-
ous values as compared to less frequent blood glucose 
values [40]. If accurate CGM systems and adapted insulin 
protocols are implemented in the ICU, further research 
is required to evaluate long-term effects on clinical out-
comes in RCTs. Insulin therapy guided by CGM did not 
impact on time in target range and glycemic variability in 
previous RCTs [13, 14, 40].
Potential areas for improvements
  • Calibration should only be performed during “steady-
state” glucose levels, and not during rapid glucose 
fluctuations [33, 39] or adapted within a special cali-
bration algorithm
  • Improved fixation method or different localization to 
avoid accidental sensor removal
  • Wireless device to avoid data gaps caused by occa-
sional disconnection during bedding or mobilization, 
as well as accidental removals
  • Integration of the continuous glucose display into 
the established patient monitor to reduce additional 
equipment
  • Inclusion of a suggestion according to the local insu-
lin treatment protocol into monitor
Limitations
Firstly, this was a point accuracy analysis, in which only 
the concurrent blood glucose sample was considered. 
The reporting of glucose trending is not possible in this 
trial. Secondly, in the clinical setting we cannot exclude 
that there is a delay between the taking of a blood sample 
and the actual analysis via blood gas analyzer, where the 
time-point is documented [12, 20]. Thirdly, not all nurses 
were familiar with the device after the initial instruc-
tions provided by the manufacturer. Fourthly, the low 
response rate to the questionnaires may bias the results 
of the nurse acceptance survey. Fifthly, due to the low 
number of actual hypoglycemic events, there is a lack of 
evidence to draw a conclusion concerning the accuracy 
during hypoglycemia. It has to be stressed that this study 
was not designed to evaluate potential benefits of CGM 
on glucose control and there was no variation to the insu-
lin protocol.
Conclusion
The Medtronic System did not perform with satisfac-
tory accuracy, feasibility or nursing acceptance when 
evaluated in 20 medical-surgical ICU patients. Low point 
accuracy and prolonged data gaps significantly limited 
the potential clinical usefulness of the CGM trend data. 
Future studies are required to determine the clinical 
value of the real-time Sentrino® glucose trend data and 
alarms, using a validated nurse-driven insulin dosing 
algorithm in order to improve the safety and efficacy of 
blood glucose control in hospitalized patients.
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